RxDoctor Payments Data

Thomas Dougherty, MD

Cardiovascular Disease · la Mirada, CANPI 1699712232

Payments from drug & device makers

$466in general payments, 2019–2025

Across 17 payments — averaging $27.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$184
  • Amgen$94
  • Pfizer$84
  • Novo Nordisk$36
  • Lilly USA, LLC$22
  • Xeris Pharmaceuticals, Inc.$19
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$466100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$466 in reported general payments places this provider in the 25th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$14,463
Medicare patients
63
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$137,885
EliquisApixaban95$101,702
MounjaroTirzepatide41$54,146
JardianceEmpagliflozin55$48,814
TrulicityDulaglutide15$28,790
EntrestoSacubitril/Valsartan12$12,095
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$7,318
Humalog Kwikpen U-100Insulin Lispro29$7,222
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$7,154
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$4,849
LantusInsulin Glargine,hum.Rec.Anlog26$4,427
Levothyroxine Sodium217$2,930
Atorvastatin Calcium544$2,759
Amiodarone Hcl37$2,421
Lidocaine15$2,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$36$137,885110 claims
PfizerEliquis$84$101,70295 claims
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30, Insulin Lispro$22$85,11284 claims
Sanofi-aventis U.S. LLCLantus$16$4,42726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in la Mirada

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →